Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 1577 - 1584 of 11454 results
F-1 Student Employment Guidance
October 3, 2022| Advisory| Viewpoint
MintzRx Newsletter — Your Prescription for the Pharmaceutical Supply Chain
October 3, 2022| Article| Viewpoint
MintzRx — Drug Pricing Update: The Inflation Reduction Act
October 3, 2022| Blog| Viewpoint
HHS, Treasury and Labor Issue More Guidance on the No Surprises Act
October 3, 2022| Blog| Viewpoint
US Needs To Double Grid Building Pace For Climate Change Law Benefits
October 2, 2022| News
Monthly TCPA Digest — September 2022
September 30, 2022| Article| Viewpoint
TCPA Litigation Update — Good News for Defendants Facing Claims Under Florida’s Mini-TCPA
September 30, 2022| Article| Viewpoint
News & Press Releases
Venture Mega-Rounds Return to Biotech
September 26, 2024
Member Cheryl Reicin was quoted in WSJ Pro Venture Capital in an article about how venture mega rounds are becoming more frequent in the biotech industry. Specifically, Cheryl discusses the need for startups to be aware of the pressures and implications that may come from larger funding rounds.
Lenovo’s Setback in Ericsson ITC Case May Impact Other SEP Disputes
September 26, 2024
Intellectual Property Division Chair Michael Renaud was quoted by IAM in an article about the ITC case between Ericsson and Lenovo and its potential implications for FRAND negotiations. While most ITC cases involving Standard Essential Patents (SEPs) have resulted in no violation findings, this case could change that.
Mintz Ranked in 2025 Edition of Chambers Canada
September 26, 2024
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.